Ventyx Biosciences Management
Management criteria checks 2/4
Ventyx Biosciences' CEO is Raju Mohan, appointed in Nov 2018, has a tenure of 6.17 years. total yearly compensation is $9.41M, comprised of 6.3% salary and 93.7% bonuses, including company stock and options. directly owns 3.24% of the company’s shares, worth $4.90M. The average tenure of the management team and the board of directors is 2.2 years and 3.7 years respectively.
Key information
Raju Mohan
Chief executive officer
US$9.4m
Total compensation
CEO salary percentage | 6.3% |
CEO tenure | 6.2yrs |
CEO ownership | 3.2% |
Management average tenure | 2.2yrs |
Board average tenure | 3.7yrs |
Recent management updates
Recent updates
We Think Ventyx Biosciences (NASDAQ:VTYX) Needs To Drive Business Growth Carefully
Nov 14Ventyx Biosciences: Ready To Escape "The Crash Cycle"
Nov 04Is Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Invest In Growth?
Jul 12Ventyx Biosciences: Slim Chances In A Fat Market (Rating Downgrade)
Jul 01Ventyx Pivots To Obesity Amid Transformation
Mar 12Here's Why We're Watching Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn Situation
Feb 15Ventyx: Too Risky Right Now After Some Poor Data
Jan 18Companies Like Ventyx Biosciences (NASDAQ:VTYX) Are In A Position To Invest In Growth
Sep 21Ventyx Biosciences (NASDAQ:VTYX) Is In A Good Position To Deliver On Growth Plans
Jun 07We're Not Very Worried About Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn Rate
Feb 20Ventyx Biosciences: Not Chasing This Rally
Sep 18We Think Ventyx Biosciences (NASDAQ:VTYX) Can Afford To Drive Business Growth
Aug 19Ventyx Biosciences GAAP EPS of -$0.39 beats by $0.06
Aug 15Ventyx Biosciences autoimmune/autoinflammatory candidate meets phase 1 goals
Jun 29We're Not Very Worried About Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn Rate
May 06We Think Ventyx Biosciences (NASDAQ:VTYX) Can Afford To Drive Business Growth
Jan 21CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Sep 30 2024 | n/a | n/a | -US$153m |
Jun 30 2024 | n/a | n/a | -US$171m |
Mar 31 2024 | n/a | n/a | -US$193m |
Dec 31 2023 | US$9m | US$596k | -US$193m |
Sep 30 2023 | n/a | n/a | -US$181m |
Jun 30 2023 | n/a | n/a | -US$158m |
Mar 31 2023 | n/a | n/a | -US$125m |
Dec 31 2022 | US$4m | US$567k | -US$108m |
Sep 30 2022 | n/a | n/a | -US$91m |
Jun 30 2022 | n/a | n/a | -US$73m |
Mar 31 2022 | n/a | n/a | -US$69m |
Dec 31 2021 | US$15m | US$423k | -US$85m |
Sep 30 2021 | n/a | n/a | -US$84m |
Jun 30 2021 | n/a | n/a | -US$79m |
Mar 31 2021 | n/a | n/a | -US$65m |
Dec 31 2020 | US$68k | US$37k | -US$28m |
Compensation vs Market: Raju's total compensation ($USD9.41M) is above average for companies of similar size in the US market ($USD1.39M).
Compensation vs Earnings: Raju's compensation has increased whilst the company is unprofitable.
CEO
Raju Mohan (66 yo)
6.2yrs
Tenure
US$9,411,949
Compensation
Dr. Raju S. Mohan, Ph.D. founded Ventyx Biosciences, Inc. in November 2018 and serves as its Chief Executive Officer and Director since then and serves as its President since November 22, 2023. Dr. Mohan h...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Executive Chairperson | 3.7yrs | US$486.29k | 0.18% $ 278.2k | |
Founder | 6.2yrs | US$9.41m | 3.24% $ 4.9m | |
Chief Scientific Officer | 6yrs | US$3.89m | 0.66% $ 994.2k | |
Interim Principal Financial Officer & Principal Accounting Officer | less than a year | no data | 0.0010% $ 1.6k | |
Chief Operating Officer | less than a year | no data | no data | |
Chief Medical Officer | less than a year | no data | no data |
2.2yrs
Average Tenure
56yo
Average Age
Experienced Management: VTYX's management team is considered experienced (2.2 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Executive Chairperson | 3.7yrs | US$486.29k | 0.18% $ 278.2k | |
Founder | 6.2yrs | US$9.41m | 3.24% $ 4.9m | |
Independent Director | 2yrs | US$834.42k | 0% $ 0 | |
Independent Director | 6.2yrs | US$417.35k | no data | |
Member of Clinical & Scientific Advisory Board | no data | no data | no data | |
Member of Clinical & Scientific Advisory Board | no data | no data | no data | |
Member of Clinical & Scientific Advisory Board | no data | no data | no data | |
Member of Clinical & Scientific Advisory Board | no data | no data | no data | |
Independent Director | 3.7yrs | US$416.29k | 0% $ 0 | |
Independent Director | 2yrs | US$837.34k | 0% $ 0 |
3.7yrs
Average Tenure
60.5yo
Average Age
Experienced Board: VTYX's board of directors are considered experienced (3.7 years average tenure).
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/01/03 06:51 |
End of Day Share Price | 2025/01/03 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Ventyx Biosciences, Inc. is covered by 11 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Edward Nash | Canaccord Genuity |
Tiago Fauth | Credit Suisse |
Chris Shibutani | Goldman Sachs |